© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Commentary
Guy's Hospital, London, UK
Correspondence and offprint requests to: David Goldsmith, Renal Unit, 6th Floor Guy's Hospital, London SE1 9RT, UK. Email: david.goldsmith@gstt.nhs.uk
Keywords: biopharmaceuticals; biosimilars; comparative testing; immunogenicity; pharmacovigilance; regulatory guidelines
| The first 10% of the full text of this article appears below. |
We are now in the fifth decade of providing clinically useful medical and surgical care for patients with chronic kidney disease (CKD). The numbers of patients requiring a plan for renal replacement therapy has risen very sharply, as has the number of patients with a recognized impairment of kidney function. Progress in medicine, increasing economic wealth in industrialized and developing countries, societal pressures and above all the significant growth of a large ageing cohort (prone to obesity, hypertension, diabetes and cardiovascular disease)